β-连环素在肝癌中的表达及其与cyclin D1表达的关系  

Expression of β-catenin in hepatocellular carcinoma and its relation with cyclin D1 expression

作　　者：曾建平[1] 易继林[1] 李兴睿[1] 杨志芳[1] 王从俊[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院普通外科,湖北省武汉市430030

出　　处：《世界华人消化杂志》2006年第1期96-99,共4页World Chinese Journal of Digestology

摘　　要：目的:探讨β-连环素(β-catenin)在肝癌中的表达及其对cyclinD1表达的影响.方法:采用免疫组织化学SP染色法检测38例肝细胞癌,8例肝硬化以及5例正常肝组织中β-catenin和cyclinD1蛋白的表达水平.结果:β-catenin在正常肝组织和肝硬化组织中呈微弱的膜表达.55.2%(21/38)的肝细胞癌组织β-catenin呈异常表达,异常表达的β-catenin主要位于癌细胞胞质.低分化、有转移的肝癌其β-catenin异常表达率明显高于高分化、无转移的肝癌.β-catenin异常表达与cyclinD1过表达显著相关(P=0.017).38例肝癌中13例(34%)显示β-catenin异常表达伴cyclinD1阳性染色,15例(39%)显示β-catenin正常表达伴cyclinD1阴性染色.结论:β-catenin的异常表达与肝癌的进展和转移有关.其机制可能是通过激活cyclinD1基因的表达,促使肝细胞增殖和恶性转化而实现.AIM： To investigate the expression of β-catenin in hepatocellular carcinoma （HCC） and its effect on the expression of cyclin D1. METHODS： The immunohistochemical SP staining technique was performed to detect the expression of β-catenin and cyclin D1 in 51 liver tissue samples, including 5 cases of normal liver, 8 cases of liver cirrhosis, and 38 cases of HCC. RESULTS： In normal and cirrhotic liver, the weak expression of β-catenin was observed in the cell membrane. The aberrant expression of β-catenin, mainly located at the cell cytoplasm, was detected in 21 （55.2%） of the 38 HCC tissues and significantly higher in the tissues with poor differentiation and metastasis than that in the ones with well differentiation and non-metastasis. There was a significant correlation between the aberrant expression of β-catenin and the over expression of cyclin D1 （P = 0.017）. Of the 38 HCC tissue samples, 13 were found aberrant expression of β-catenin combined with positive expression of cyclin D1 （34%）, and 15 were found normal expression of β-catenin combined with negative cyclin D1 expression （39%）. CONCLUSION： The aberrant expression of β-catenin is related with the progression and metastasis of HCC, and exhibits its effect mainly by the transactivation of cyclin D1 gene.

关 键 词：肝细胞癌 β—catenin CYCLIN D1 免疫组织化学 

分 类 号：R735.7[医药卫生—肿瘤]